Pathology: metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA); metastatic/advanced RCC (mRCC) - 2nd line (L2);
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) | metastatic/advanced RCC (mRCC) - 2nd line (L2) | ||
CheckMate 914, 2017 | CheckMate 025, 2015 | ||
nivolumab alone | 2 | T1 | T1 |
nivolumab plus ipilimumab | 0 | T0 | |
everolimus | 0 | T0 |